J. Nathan Davis

The t(12;21) Translocation Converts AML-1B from an Activator to a Repressor of Transcription

Scott W. Hiebert, Wuhua Sun, J. Nathan Davis et al. · Molecular and Cellular Biology · 1996 · 278 citations · Full text

Lymphocyte Development, T-regulatory Cell, Immunology +16

A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity.

Alex A. Adjei, Charles Erlichman, J. Nathan Davis et al. · PubMed · 2000 · 243 citations

Chemoprevention Strategy, Pathology, Pharmacotherapy +17

Gfi‐1 attaches to the nuclear matrix, associates with ETO (MTG8) and histone deacetylase proteins, and represses transcription using a TSA‐sensitive mechanism

Laura McGhee, Josh Bryan, Liza T Elliott et al. · Journal of Cellular Biochemistry · 2003 · 120 citations

Comparison of potential markers of farnesyltransferase inhibition.

Alex A. Adjei, J. Nathan Davis, Charles Erlichman et al. · PubMed · 2000 · 119 citations

Molecular Pharmacology, Tumor Biology, Ft Inhibition +15

Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines.

Alex A. Adjei, J. Nathan Davis, Laura M. Bruzek et al. · PubMed · 2001 · 96 citations

Chemoprevention Strategy, Drug Sequencing, Cancer Biology +17